A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Nebivolol (Primary)
- Indications Left ventricular dysfunction
- Focus Biomarker; Therapeutic Use
- Acronyms NEBIDYS
- 30 Apr 2021 Biomarkers information updated
- 31 Jul 2012 New trial record